Theravance Respiratory Company, LLC

Theravance, Inc.

Weatherford Technology Holdings, LLC

USA Sands, LLC

Richard D Wilson

Adam D Hughes

Yan Chen

Melissa Fleury

Eric L Stangeland

John R Jacobsen

Rose Yen

Daniel Byun

Mathai Mammen

Craig Husfeld

Yu-Hua Ji

Li Li

Sarah Dunham

Ioanna Stergiades

Trevor Mischki

David A Oare

Miroslav Rapta

James W Chambers

Robert S Chao

Jennifer Bolton

Lisa Williams

Axel James Perez

Dennis Duke

System and method for detecting the presence at a distance of materials utilizing the atomic structure and characteristics of the elements in the chemicals comprising the material.

Detection system

The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising a compound of formula I: or a pharmaceutically acceptable salt thereof.

Diamide compounds having muscarinic receptor antagonist and &#x3b2;2 adrenergic receptor agonist activity

Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity

The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising from about 0.05 &#x3bc;g/mL to about 10 mg/mL of a compound of formula I: or a pharmaceutically acceptable salt thereof.

Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity

A sealing assembly for sealing against a piece of oilfield equipment in a wellbore. The sealing assembly has a support housing and the support housing defines an inner wall and a port configured for fluid communication with the wellbore. Such inner wall defines a stop shoulder, and the support housing has a limit structure proximate one or both end(s). A sealing element is contained within the support housing. A ring is connected to the sealing element at one or both end(s). Each ring is configured for slidable movement along the inner wall of the support housing and further configured to float between the stop shoulder and the limit structure.

Sealing element mounting

This invention relates to a compound of formula I: 

[object Object]

The invention provides diamide compounds having muscarinic receptor antagonist and &#x3b2;adrenergic receptor agonist activity, pharmaceutical compositions thereof, and methods of treatment using the same.

This invention relates to a compound of formula I:  or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and &#x3b2;adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.

This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds.

Substituted 4-amino-benzylpiperidine compounds

The invention relates to crystalline free base forms of biphenyl-2-ylcarbamic acid 1-[2-(4-{[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also relates to pharmaceutical compositions containing or prepared from such crystalline forms; processes and intermediates useful for preparing such crystalline forms; and methods of using such crystalline forms to, for example, treat a pulmonary disorder.

Crystalline forms of a dimethylphenyl compound

Substituted 4-amino-1-benzylpiperidine compounds

This invention provides 4-amino-1-(pyridylmethyl)piperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome and chronic obstructive pulmonary disease, using such compounds.

Growing community of inventors

Orinda, CA, United States of America

Richard D Wilson